News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
33 Results
Section
Business (4)
News (4)
Tag
Alliances (2)
Diagnostics (3)
Events (1)
People (2)
Research institute (1)
Date
Last 365 days (1)
2024 (1)
2023 (2)
2022 (3)
2021 (10)
2020 (4)
2019 (3)
2018 (4)
2017 (4)
2014 (1)
33 Results for "prevencio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioForest
Prevencio and Emory Winship Cancer Institute AI-driven HART CVE Test Data Predicts Risk of Adverse Cardiovascular Effects Associated with Prostate Cancer Therapy
Prevencio, Inc. announces the presentation of data using its Artificial Intelligence driven HART CVE blood test for prediction of subsequent adverse cardiac events in prostate cancer patients undergoing radiotherapy and androgen deprivation therapy.
February 7, 2024
·
4 min read
BioForest
Massachusetts General Hospital Researchers and Prevencio Announce AI-driven HART® CVE Blood Test Accuracy for Patients with Coronary Chronic Total Occlusion
Prevencio, Inc. announces the presentation of patient data demonstrating that its Artificial Intelligence -driven HART® CVE blood test is highly accurate for risk assessment in patients with total blockage of a heart artery, also known as coronary Chronic Total Occlusion.
October 24, 2023
·
4 min read
Business
Prevencio Announces Agreement with Alivio Health Expanding Access to AI-Driven Cardiac HART Tests Offered by Atlas Genomics
Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests.
July 19, 2022
·
4 min read
BioForest
Prevencio Announces National Medicare Pricing for Company’s Three AI-Powered HART® Cardiac Blood Tests
Prevencio, Inc., The AI-Powered Cardiac Blood Test Company, announced the Centers for Medicare & Medicaid Services has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART® cardiac blood tests.
January 10, 2023
·
3 min read
BioForest
Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate for Predicting Major Cardiac Events in Patients with Chronic Kidney Disease
Prevencio, Inc. today announces the presentation of patient data demonstrating its Artificial Intelligence (AI)-driven HART CVE blood test is highly accurate in determining whether a person with chronic kidney disease (CKD) will have a heart attack or major adverse cardiac event within the next two years.
November 3, 2022
·
5 min read
BioForest
Massachusetts’s General Hospital Study Demonstrates Prevencio’s AI-driven HART CVE Blood Test Highly Accurate in Patients with Diabetes for Predicting Heart Attack, Stroke, and Cardiac Death Risk
Prevencio, Inc. today announces the presentation of patient data demonstrating its Artificial Intelligence (AI)-driven HART CVE blood test is highly accurate in determining whether a person with diabetes will have a heart attack or major cardiac event within the next year.
April 12, 2022
·
5 min read
BioForest
Prevencio’s AI-driven HART CVE Blood Test Demonstrates Usefulness in Spinal Cord Injury Patients
Prevencio, Inc. today announces the presentation of data acquired in patients with spinal cord injury demonstrating that its Artificial Intelligence (AI)-driven HART CVE blood test is useful, low risk and as accurate as currently used cardiac risk imaging tests that require radiation exposure.
October 4, 2021
·
4 min read
BioForest
Prevencio’s Novel AI-Driven HART CADhs Blood Test Significantly More Accurate than Troponin for Obstructive Heart Disease
Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.
September 1, 2021
·
4 min read
BioForest
Prevencio and Seattle Children’s Research Institute Present Highly Accurate, AI-driven HART KD Data on First Blood Test for Kawasaki Disease at Premiere International Kawasaki Disease Scientific Sessions
Prevencio, Inc. announces presentation of highly accurate data on an Artificial Intelligence -driven blood test for Kawasaki disease at the International Kawasaki Disease Scientific Sessions in Japan.
November 9, 2021
·
5 min read
BioForest
Prevencio Announces U.S. Patent Issuance for Novel, Artificial Intelligence-driven Blood Test for Cardiac Risk
Prevencio, Inc. today announces the United States Patent Office’s issuance of a patent for its highly accurate blood test, HART CVE, for a patient’s one-year risk of heart attack, stroke, or cardiovascular death.
August 4, 2021
·
4 min read
1 of 4
Next